Reply to Letter by Akboga et al Entitled “Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?”
Restricted accessReplyFirst published online May, 2020
Reply to Letter by Akboga et al Entitled “Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?”
BalamirIAtesITopcuogluCTurhanT. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69:609–16.
2.
AkbogaMKOkutucuSSabanogluCYaylaCErtemAGEfeTH. Are endocan and ischemia-modified albumin reliable biomarkers for endothelial dysfunction in type 2 diabetes mellitus?Angiology. 2020;71:479–80.
3.
BaldassarreMPAAndersenAConsoliAKnopFKVilsbollT. Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes Obes Metab. 2018;20:1350–60.
4.
BolatkaleMDugerMUlferG, et al.A novel biochemical marker for community-acquired pneumonia: Ischemia-modified albumin. Am J Emerg Med. 2017;35:1121–25.
